al., et

Shah, Nirav N.

Vij, Ravi

English

Digital Commons@Becker

Shah et al. Blood Cancer Journal           (2021) 11:82 https://doi.org/10.1038/s41408-021-00472-w Blood Cancer JournalCORRECT ION Open Ac c e s sCorrection: Allogeneic transplantation in elderlypatients ≥65 years with non-Hodgkin lymphoma:a time-trend analysisNirav N. Shah, Kwang Woo Ahn, Carlos Litovich, Anna Sureda, Mohamed A. Kharfan-Dabaja , Farrukh T. Awan,Siddhartha Ganguly, Usama Gergis, David Inwards, Reem Karmali, Alexsandr Lazaryan, Lazaros Lekakis, Pashna Munshi,Sunita Nathan, Ayman A. Saad, Melhem Solh, Amir Steinberg, Ravi Vij, William A. Wood, Timothy S. Fenske,Sonali Smith and Mehdi HamadaniCorrection to: Blood Cancer Journalhttps://doi.org/10.1038/s41408-019-0261-1published online 3 December 2019The original version of the article contained incorrectacknowledgements. The correct ones are:AcknowledgementsCIBMTR Support List, The CIBMTR is supported primarily by Public HealthService Grant/Cooperative Agreement U24CA076518 from the National CancerInstitute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and theNational Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement U24HL138660 from NHLBI and NCI; GrantR21HL140314 from NHBLI; Grant U01HL128568 from NHLBI; a contractHHSH250201700006C with Health Resources and Services Administration(HRSA/DHHS); Grants N00014-18-1-2888 and N00014-17-1-2850 from theOffice of Naval Research HHSH250201700006C; grants from *ActiniumPharmaceuticals, Inc.; Adaptive Biotechnologies; *Amgen, Inc.; Anonymousdonation to the Medical College of Wisconsin; *Anthem, Inc.; Astellas PharmaUS; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.;Boston Children’s Hospital; *Bristol Myers Squibb Co.; *Celgene Corp.;Children’s Hospital of Los Angeles; *Chimerix, Inc.; *CSL Behring; *CytoSenTherapeutics, Inc.; Dana Farber Cancer Institute; *Daiichi Sankyo Co., Ltd.; FredHutchinson Cancer Research Center; *Gamida-Cell, Ltd.; Gilead Sciences, Inc.;*GlaxoSmithKline (GSK); HistoGenetics, Inc.; Immucor; Incyte Corporation;Janssen Biotech, Inc.; *Janssen Pharmaceuticals, Inc.; Janssen Scientific Affairs,LLC; *Jazz Pharmaceuticals, Inc.; Karius, Inc.; Karyopharm Therapeutics, Inc.;*Kite, a Gilead Company; *Magenta Therapeutics; Medac GmbH; The MedicalCollege of Wisconsin; Mediware; Merck & Company, Inc.; *Mesoblast;MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *MiltenyiBiotec, Inc.; Mundipharma EDO; National Marrow Donor Program; NovartisOncology; Novartis Pharmaceuticals Corporation; *Omeros Corporation;*Oncoimmune, Inc.; PCORI; *Pfizer, Inc.; *Phamacyclics, LLC; PIRCHE AG;*Regeneron Pharmaceuticals, Inc.; REGiMMUNE Corp.; *Sanofi Genzyme;*Seattle Genetics; *Shire; Sobi, Inc.; Spectrum Pharmaceuticals, Inc.; St. Baldrick’sFoundation; Swedish Orphan Biovitrum, Inc.; *Takeda Oncology; University ofMinnesota; University of Pittsburgh; University of Texas-MD Anderson;University of Wisconsin-Madison and Viracor Eurofins. The views expressed inthis article do not reflect the official policy or position of the National Instituteof Health, the Department of the Navy, the Department of Defense, HealthResources and Services Administration (HRSA), or any other agency of the U.S.Government. *Corporate members: Kristina Jacobs for administrative support.The original article has been updated.© The Author(s) 2021OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproductionin any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate ifchangesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. Ifmaterial is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtainpermission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.Blood Cancer Journal1234567890():,;1234567890():,;1234567890():,;1234567890():,;

Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: A time-trend analysis

https://digitalcommons.wustl.edu/cgi/viewcontent.cgi?filename=1&article=9566&context=open_access_pubs&type=additional

Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: A time-trend analysis

Abstract

Similar works

Full text

Available Versions

Digital Commons@Becker